Spine Surgery for Adhesions in Patients Evaluated for Efficacy and Safety of MedicurtainⓇ (Pivotal Study)

NCT ID: NCT04688281

Last Updated: 2021-09-29

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: NA
• Total Enrollment: 87 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2011-10-11
• Study Completion Date: 2013-03-25

Brief Summary

This study was designed to evaluate the efficacy and safety of Medicurtain®, an antiadhesion barrier in patients who underwent In Situ Decompression for single level and unilateral herniated lumbar intervertebral disc. Subjects were randomly assigned either into Medicurtain® treatment group or control group. Adhesion formations between the two groups at 12 weeks after surgery were compared by using MRI-applied scar score, ODI (Oswestry Disability Index) and VAS.

Detailed Description

This study was multicenter, randomized, evaluator-blind, parallel-controlled trial. A subject aged between 20~70 years old who was reserved for In Situ Decompression for single level and unilateral herniated lumbar intervertebral disc considered to be eligible for study entry. Subject screening was conducted at Visit 1 (screening period) to determine study based on the results of the examination for the spine surgery. Subject who met the inclusion/exclusion criteria were randomly assigned into either the treatment and control group at Visit 2 (Baseline: 0day) and received the defined treatment according to the protocol.

Direct evaluation of the level of adhesion around surgical area was analyzed by measuring peridural fibrosis and scar score through MRI (Total MRI scar score). Jeffrey S. Ross et al. reported that in evaluating scar in disc region, MR has been used by many researchers and shows 96% accuracy in identifying scar in disc region. Also measuring the level of fibrosis in surgical wounds through MRI scar score has already been widely used in many large-scale studies and shows almost perfect conformity degree I inter-and intra-observer reading results.

Therefore based on literatures, this study measures the level of adhesion in surgical wounds through MRI scar score, which has been validated and widely used in similar studies. Using MRI 3 months after surgery, the level of scar in lumbar spinal column is evaluated. All MRI images should be evaluated by one radiologist unless the randomization of the treatment group and control group is revealed. Peridural fibrosis is evaluated on the improved and unimproved state of axial T1-weighted image contrast. In MR image evaluation, location of peridural fibrosis to 5 consecutive axial sections that are 4mm thick around the intervertebral disc is recorded; these 5 levels are divided into quadrant which are divided by 2 straight lines vertical to the center of thecal sac.

Degree of peridural fibrosis is scaled by scar grading scale in 0~4 point range according to the dimension of the quadrant filled with scar. Record the scar score of each quadrant of 5 levels (total of 20 grades-scar score method). The measured scar scores of the investigational device group and control device group are compared and evaluated with total of 20 scores on each quadrant of 5 levels (Total MRI score).

After 2 weeks (2 weeks±3days) of the index surgery, following tests were performed to evaluate the subject's condition and adverse events at before signing on the informed consent and after the surgery. The investigation device is composed of mainly Sodium Hyaluronate(HA) and Hydroxyethylstarch(HES) which were degraded in the liver and excreted from the kidney, therefore, it is included liver and kidney function test and blood coagulation test since abnormal function of blood coagulation can increase adhesion around the surgical wound area.

Conditions

Intervertebral Disc Disorder; Thoracic Intervertebral Disc Disorders; Thoracolumbar Intervertebral Disc Disorders; Lumbosacral Intervertebral Disc Disorders; Tissue Adhesion, Surgery-Induced

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: PREVENTION
• Blinding Strategy: SINGLE

Study Groups

GUARDIX-SG®

Treat GUARDIX-SG 5ml prefilled syringe after surgery

Group Type: ACTIVE_COMPARATOR

GUARDIX-SG®

Intervention Type: DEVICE

GUARDIX-SG® 5ml prefilled syringe

Medicurtain®

Treat Medicurtain® 5ml prefilled syringe after surgery

Group Type: EXPERIMENTAL

Medicurtain®

Intervention Type: DEVICE

Medicurtain® 5ml prefilled syringe

Interventions

Medicurtain®

Medicurtain® 5ml prefilled syringe

Intervention Type: DEVICE

GUARDIX-SG®

GUARDIX-SG® 5ml prefilled syringe

Intervention Type: DEVICE

Eligibility Criteria

Inclusion Criteria

• Aged between 20 ~ 70 years old
• Subject who is reserved with surgery for single-level or unilateral herniated lumbar Intervertebral disc
• Subject who is scheduled for In Situ Decompression(laparoscopic hysterectomy)
• Subject who does not respond to non-surgical treatment for at least past 6 weeks or require emergency surgery due to neural paralysis or excruciating pain
• Subject or his or her legal representative who signed and informed consent

Exclusion Criteria

• Subject with multi-level or far lateral herniated lumbar intervertebral disc
• Subject with degenerative spinal disease or scoliosis
• Subject requires spinal fusion surgery
• Subject with severe liver or kidney disease
• Subject with lymph fluid or blood coagulation disease or medicated with blood clotting drug.
• Subject on oral or non-oral anti-diabetic drug or hypoglycemic drug
• Subject with suppressed immunity or autoimmune disease
• Subject with severe systemic disease
• Subject with infectious disease or healing disorder that may prevent normal healing process after surgery.
• Subject contraindicated with MRI scanning.
• Pregnant or lactating women
• Subject participated in other clinical trial within 30 days prior to the trial
• Subject justified not eligible to participate in the trial by Investigator

• Subject undergone previous spinal surgery
• Subject treated steroid epidural injection within 2 weeks or take oral steroid within 24 hours after surgery
• Subject medicated aspirin or non-steroid anti-inflammatory drug within 7 days after surgery
• Subject received myelogram or lumbar puncture within 24 hours after surgery

• Minimum Eligible Age: 20 Years
• Maximum Eligible Age: 70 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Shin Poong Pharmaceutical Co. Ltd.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Chong-Suh Lee, MD, PhD

Role: PRINCIPAL_INVESTIGATOR

Samsung Medical Center, Gangnam-gu, Ilwon-dong 50, Seoul, South Korea

Eun-Sang Kim, MD, PhD

Role: PRINCIPAL_INVESTIGATOR

Samsung Medical Center, Gangnam-gu, Ilwon-dong 50, Seoul, South Korea

Ki-Tack Kim, MD, PhD

Role: PRINCIPAL_INVESTIGATOR

Kyung Hee University Hospital, Gangdong-gu, Sangil-dong 149, Seoul, South Korea

Joomyung Kim, MD, PhD

Role: PRINCIPAL_INVESTIGATOR

Samsung Medical Center, Gangnam-gu, Ilwon-dong 50, Seoul, South Korea

Yong Cheol Yoon, MD, PhD

Role: PRINCIPAL_INVESTIGATOR

Hallym University Medical Center, Pyeongchon-dong 896, Anyang, Gyeonggi-do, South Korea

Bong-Soon Chang, MD, PhD

Role: PRINCIPAL_INVESTIGATOR

Seoul National University Hospital , Jongro-gu, Yeongeon-dong, Seoul, South Korea

Byung-Joon Shin, MD, PhD

Role: PRINCIPAL_INVESTIGATOR

Soonchunhyang University Hospital , Yongsan-gu, Daesagwan-ro 59, Seoul, South Korea

Locations

Samsung Medical Center

Seoul, Gangnam-gu, Ilwon-dong 50, South Korea

Countries

South Korea

Other Identifiers

UMT2011-SP-MC-03

Identifier Type: -

Identifier Source: org_study_id